Table 3 The change of quality of life from baseline through follow-up.

From: A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer

 

3 months

6 months

9 months

12 months

18 months

24 months

30 months

IPSS

 n, paired values

215

160

123

117

72

63

42

 Baseline

7.1 ± 5.8

7.1 ± 5.9

7.7 ± 5.9

7.4 ± 6.0

7.7 ± 6.4

8.5 ± 6.7

8.6 ± 6.3

 Follow-up

8.2 ± 5.9

6.1 ± 5.5

7.2 ± 6.5

6.4 ± 5.0

7.8 ± 6.4

8.1 ± 5.6

8.7 ± 8.2

 Change

1.1

−1.0

−0.5

−1.1

0.2

−0.3

0.1

 95% CI

0.2 to 1.9

−0.2 to −1.8

−1.5 to 0.6

−0.04 to −2.1

−1.2 to 1.5

−2.0 to 1.2

−2.2 to 2.5

 p value

0.015

0.017

0.41

0.04

0.82

0.65

0.90

IIEF-5

 n, paired values

139

124

95

89

55

36

28

 Baseline

16.0 ± 8.6

15.7 ± 8.6

14.9 ± 8.6

15.3 ± 8.6

14.4 ± 8.6

16.0 ± 9.0

15.0 ± 9.1

 Follow-up

12.1 ± 8.7

11.5 ± 8.4

11.5 ± 8.3

11.2 ± 8.5

10.8 ± 8.5

12.3 ± 9.0

10.9 ± 9.1

 Change

−3.8

−4.2

−3.4

−4.0

−3.7

−3.8

−4.1

 95% CI

−4.9 to −2.7

−5.4 to −3.1

−4.7 to −2.0

−5.5 to −2.6

−5.6 to −1.7

−6.9 to −0.6

−7.6 to −0.5

 p value

<0.001

<0.001

<0.001

<0.001

<0.001

0.02

0.03

  1. IPSS International Prostate Symptom Score, QOL Quality of Life, IIEF The International Index of Erectile Function, CI Confidence Interval.